Dr.FinanceWAR:DRF +1.30%36 EBITDA Margin % is -46.43% as of Dec. 2025. GuruFocus rates WAR:DRF with a GF Score™ of 36/100 and a GF Value™ of zł0.50 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 414 Credit Services companies, Dr.Finance ranks worse than 78.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dr.Finance's EBITDA for the
three
months ended in Dec. 2025 was zł-0.09 Mil. Dr.Finance's Revenue for the
three
months ended in Dec. 2025 was zł0.20 Mil. Therefore, Dr.Finance's EBITDA margin for the quarter that ended in Dec. 2025 was -46.43%.
Dr.Finance (WAR:DRF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dr.Finance EBITDA Margin % Related Terms
Dr.Finance EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dr.Finance's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Credit Services subindustry, Dr.Finance's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr.Finance EBITDA Margin % vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Dr.Finance's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dr.Finance's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr.Finance (WAR:DRF) has a EBITDA Margin % of -46.43% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr.Finance and its competitors. According to the industry distribution chart, Dr.Finance ranks #324 out of 414 companies in the Credit Services industry, placing it in the top 78.3%.
Is Dr.Finance's EBITDA Margin % too high?
Dr.Finance's current EBITDA Margin % is -46.43%. Based on the distribution chart, Dr.Finance ranks #324 out of 414 companies in the Credit Services industry, which is in the bottom quartile relative to peers. Overall, Dr.Finance has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr.Finance's EBITDA Margin % compare to V and MA?
According to the Credit Services industry distribution chart, Dr.Finance ranks #324 out of 414 companies for EBITDA Margin %. This places Dr.Finance in the lower half of its industry. The industry median EBITDA Margin % is 20.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Credit Services company?
The median EBITDA Margin % among Credit Services companies is 20.91, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr.Finance and its competitors. For the Credit Services industry, the median EBITDA Margin % is 20.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr.Finance's current EBITDA Margin % is -46.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr.Finance stock overvalued right now?
Based on GuruFocus' analysis, Dr.Finance (WAR:DRF) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.50, compared to a current price of zł1.17 — trading 133% above its estimated fair value. The current EBITDA Margin % is -46.43%. Dr.Finance's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dr.Finance (WAR:DRF), the current EBITDA Margin % is -46.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr.Finance (WAR:DRF) Overvalued in 2026?
Based on GuruFocus' analysis, Dr.Finance stock appears to be overvalued.
The current stock price of zł1.17 is trading 133% above its estimated GF Value™ of zł0.50.
GuruFocus considers Dr.Finance to be Significantly Overvalued.
Key valuation signals for WAR:DRF:
EBITDA Margin %: -46.43%
GF Value™: zł0.50 vs. price of zł1.17 (133% above fair value)
No single metric tells the full story. See the WAR:DRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr.Finance SA is a financial intermediary in the sale of loans and other financial products. It operates in the business of Working capital loans, Investment loans, Leasing, and Factoring.
36GF Score
Get the complete analysis for WAR:DRF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:DRF has been successfully added to your 
